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Introduction
Hypertension is an uncommon but significant prob-
lem in neonates and infants. The incidence of hyper-
tension in neonates is not high, with published
incidence ranging from 0.2% to 3%.1,2 Hypertension
in neonates or infants may develop secondary to com-
plications of catheterization, certain medications, or
be a sign of an underlying renal or cardiac disease. In
most cases, hypertension may resolve, but some
infants may require long-term treatment.2
Here, we report a high-risk premature infant who
suffered from hypertension and discuss his possible
related medications and underlying diseases.
Case Report
This male infant was extremely premature, born with
emergent cesarean section due to maternal abruptio
placenta. His Apgar scores were 4 at 1 minute and 6
at 5 minutes. Gestational age was 27 weeks, and his
birth weight was only 728 g.
Reviewing the medical history of this premature infant
during admission, there were multiple serious problems,
including respiratory distress syndrome, intraventricular
hemorrhage, pulmonary hemorrhage, patent ductus
arteriosus (PDA), pericardial effusion, heart failure,
hypertension, repeated sepsis, anemia, thrombocytope-
nia, chronic lung disease, and progressive liver damage.
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Due to respiratory distress syndrome with respiratory
failure (Figure 1A), the patient had been intubated and
treated with exogenous surfactant and high-frequency
oscillatory ventilation since birth. Umbilical arterial and
venous lines were inserted for 16 and 14 days, respec-
tively. He had been ventilated for 17 days initially and
reintubated for the following 22 days because of respira-
tory failure complicated with severe pulmonary hemor-
rhage, PDA, heart failure, sepsis, upper gastrointestinal
bleeding and unstable vital signs. In addition, he was
intubated again for 4 days due to sepsis when he was
4 months old. Between and after intubations, his respi-
ration was supported with oxygen by nasal-prong con-
tinuous positive airway pressure (CPAP) or nasal cannula
until discharge. Therefore, the respiratory conditions are
compatible with the diagnosis of chronic lung disease
(CLD) and/or bronchopulmonary dysplasia (BPD).
Hypotension with low blood pressure (39/19
mmHg) was found early after birth, and dopamine was
used to maintain blood pressure and renal blood flow
(Figures 2 and 3). Unfortunately, significant hyperten-
sion was noted when the patient was 41 days old, with
a peak systolic blood pressure (SBP) of 125 mmHg.
Figure 2 shows the average SBP and diastolic blood
pressure (DBP) of the infant on each day of his
admission. SBP spontaneously returned to lower than
100 mmHg 4 days later. However, high SBP (>100
mmHg) was observed occasionally when the infant
was 116 days old, and persisted before discharge.
During that period, there were 16 days (16.8%) when
SBP was higher than 100 mmHg and 70 days (73.7%)
when it was higher than 90 mmHg (Figure 2).
Due to anemia, the patient received multiple trans-
fusions of packed red blood cells. In addition, ery-
thropoietin (EPO) injection was also used when the
infant was 92–106 days old and 151–173 days old
(mean dosage of EPO, 580–710 IU/kg/week). SBP
was around 76–94 mmHg during the 1st period of
time, and 83–105 mmHg during the 2nd period of
time. After consultation with a pediatric nephrologist,
possible hypertension caused by the use of EPO was
considered. Therefore, the use of EPO was stopped.
Serum renin measured before EPO was stopped 
was 46.20 pg/mL; it had decreased to 19.57 pg/mL
2 weeks later. Renal Doppler ultrasonography also
showed normal blood flow over bilateral kidneys.
With the use of captopril, SBP decreased to lower
than 90 mmHg. However, blood pressure went back
to being unstable after stopping captopril. The use of
EPO, captopril, and all possible related medications
are shown in Figure 3A.
PDA and pulmonary hypertension had been diag-
nosed by cardiac ultrasonography when the patient
was 2 days old. He was treated with fluid restriction,
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Figure 1. Chest X-ray films for the premature infant: (A) appearance of ground-glass pattern at 1 day of age; (B) cardiomegaly and
chronic lung disease at 150 days of age.
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Figure 2. Average daily systolic and diastolic blood pressures of
the premature infant during hospitalization.
but indomethacin was not given until he was 30 days
old because of massive pulmonary hemorrhage, gastric
bleeding, sepsis, and unstable vital signs during the 1st
month of life. Since cardiac ultrasonography still showed
PDA (0.21cm) with the presence of minimal pericardial
effusion, indomethacin was given (0.2 mg/kg/dose,
3 doses/course) for 2 courses between 31 and 35 days
of age. After that, the PDA was found to be closed, but
opened again 3 times. Therefore, indomethacin was
used for another 3 courses between the age of 37 and
65 days (Figure 3A). Unfortunately, reopened PDA
(residual duct 0.1 cm) with pericardial effusion (0.2–
0.3 cm) was still observed when the patient was 100
days old. Cardiomegaly and pericardial effusion were
both persistently observed. Chest X-ray taken when
he was 150 days old revealed significant cardiomegaly
(Figure 1B).
Repeated infections, including bacteremia, pneumo-
nia, and fungemia were found in this extremely prema-
ture infant. During hospitalization, he needed multiple
antimicrobial drugs to control infections, including
fluconazole, amphotericin B, vancomycin, teicoplanin,
meropenem, and imipenem (Figure 3B). The proven
organisms included Candida tropicalis, Staphylococcus
capitis, Staphylococcus epidermidis, coagulase-negative
Staphylococcus, Acinetobacter baumannii, Pseudomonas
aeruginosa and Escherischia coli.
Because of extreme prematurity, poor intestinal
absorption of breast milk and semi-elemental formula,
he received total parenteral nutrition (TPN) for a long
time. However, body weight gain was seriously inter-
rupted by the episodes of sepsis. TPN-related cholestatic
jaundice, hepatomegaly and complication with cirrhotic
change occurred gradually.
The patient was transferred to the intermediate
nursery when he was 7 months of age and was dis-
charged 1 week later (215 days old; weight, 1,765 g).
Unfortunately, he was admitted again 2 weeks later
due to respiratory distress, suspected sepsis, and hepatic
failure with massive ascites. His SBP was around
85–110 mmHg and DBP was around 55–80 mmHg
when his condition was stable. However, sick sinus
syndrome and intractable hypoglycemia were later found.
He died 2 months later with multiorgan failure.
Discussion
Neonatal hypertension is an uncommon but significant
complication in intensive cases. Although the incidence
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Figure 3. Umbilical catheterizations and medications in the premature infant during hospitalization.
of hypertension in neonates and infants is low, prema-
ture and sick infants are at high risk.3 Hypertension in
neonates and premature infants is best defined as SBP
and/or DBP higher than the 95th percentile for those
infants’ age and gender.3,4 Studies in both term and
preterm infants have demonstrated that blood pressure
in neonates increases with gestational, postconceptual
age, and birth weight.4–6 According to this, the pre-
sented case definitely experienced hypertension at the
age of 41 days. During the later stage (between 116
and 215 days old), the infant’s corrected age was 1–4
months old. The 95th percentile of SBP for that age in
male infants is 105–110mmHg.7 Even though the SBP
was not higher than 110 mmHg, 16% of that duration
had SBP higher than 100 mmHg. Thus, the diagnosis
of hypertension of this presented case is controversial
because of his relatively low body weight (around
1,600–1,800 g) during that period of time. Therefore,
considerations of both age and body weight are crucial
for the diagnosis and treatment of hypertension in
young infants.
The causes of hypertension in neonates are numer-
ous, with the 2 largest categories being renovascular
and other renal parenchymal diseases.8–11 The possible
etiologies of neonatal hypertension are summarized
from reported articles and listed in Table 1.3,9–20 As
shown, umbilical artery catheter-associated thromboem-
bolism affecting either the aorta and/or renal arteries
probably accounts for the majority of cases of hyper-
tension seen in the typical neonatal intensive care unit
(NICU). A clear association between use of umbilical
arterial catheters and development of arterial thrombi
was demonstrated in the early 1970s by Neal et al.12
In our case, an umbilical catheter was inserted for a total
of 16 days, so there is probably a high correlation with
his hypertension.
Hypertension has been reported to be a conse-
quence of BPD.13,14 In a study of 65 infants discharged
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Table 1. Conditions associated with hypertension in neonates and infants3,9–20
Renovascular hypertension Endocrine disorder
– Aortic or renal thromboembolism related to – Congenital adrenal hyperplasia 
umbilical artery catheterization – Hyperaldosteronism
– Congenital stenosis or hypoplasia of renal or – Hyperthyroidism
aortic artery
Tumors
– Compression of renal artery
– Neuroblastoma 
– Idiopathic arterial calcification
– Wilms’ tumor
Renal causes of hypertension
Neurologic causes
Congenital
– Intracranial hypertension
– Polycystic kidney disease
– Drug withdrawal
– Renal hypoplasia
– Seizure
– Hydronephrosis
Acquired diseases Iatrogenic causes
– Renal obstruction following surgical correction – Hypervolemia secondary to excess administration of sodium 
– Acute tubular necrosis or fluids
– Interstitial nephritis
Medications
– Acute renal failure
– Dexamethasone
BPD (chronic lung disease) – Pancuronium 
Genetic causes – Indomethacin
Single-gene disorder – Adrenergic agents
– Liddle’s syndrome – Theophylline
– Pseudohypoaldosteronism type II – Caffeine
Malformation syndrome – Vitamin D intoxication
– William’s syndrome (renal artery stenosis) – Phenylephrine
– Turner’s syndrome (aortic coarctation) – Erythropoietin?
Cardiovascular – Amphotericin B?
– Coarctation of thoracic aorta
ECMO
– PDA
Antenatal factors
Surgical repair of an abdominal wall defect
– Antenatal steroid administration
– Maternal hypertension
BPD = bronchopulmonary dysplasia; PDA = patent ductus arteriosus; ECMO = extracorporeal membranous oxygenation.
from a NICU, the incidence of hypertension in infants
with BPD was 43%, versus an incidence of 4.5% in
infants without BPD.13 Investigators were unable to
identify a clear cause of hypertension, but postulated
that hypoxemia might be involved. Over half of the
infants with BPD who developed hypertension did
not manifest it until discharged from the NICU, high-
lighting the need for measurement of blood pressure in
NICU “graduates”, whether or not they have lung
disease.21 Alagappan and Malloy also found that hyper-
tension was twice as common in very low-birth weight
infants with BPD compared to the incidence in all very
low-birth weight infants.14 Development of hyperten-
sion appeared to be correlated with the severity of
pulmonary disease, as all of the hypertensive infants
required supplemental oxygen and aminophylline. A
greater need for diuretics and bronchodilators has also
been shown to correlate with the development of hyper-
tension in infants with severe BPD.15 Our case needed
long-term intubation with mechanical ventilation, nasal
CPAP, and oxygen support for more than 7 months.
BPD and/or CLD is a definite diagnosis. Thus, BPD
likely contributed to his hypertension during the later
period of admission.
Hypertension in high-risk premature infants may
also develop later, even following discharge from the
NICU. In 1987, Friedman and Hustead reported hy-
pertension (defined as SBP >113mmHg on 3 consecu-
tive visits over 6 weeks) in 2.6% of infants discharged
from their NICU.21 The diagnosis of hypertension was
made in these infants at a mean corrected age of approx-
imately 2 months. Infants in this study who developed
hypertension tended to have lower initial Apgar scores
and slightly longer NICU stays than infants who re-
mained normotensive, indicating that sicker babies have
a greater risk of developing hypertension. Although the
number of babies affected is likely to be relatively small,
blood pressure screening has been suggested to be in-
cluded in the follow-up of NICU graduates, especially
those with more complicated NICU courses.21 Our case
also had a low Apgar score and very critical conditions
since birth; therefore, he was at a high risk of developing
hypertension.
There have been many drugs reported to be related
with neonatal hypertension (Table 1). Dexamethasone
and aminophylline were the most often reported to have
correlations to neonatal hypertension.16 In addition,
high doses of adrenergic agents, prolonged use of pan-
curonium, or administration of phenylephrine oph-
thalmic drops were also reported to raise blood pressure
in neonates.17 Such hypertension typically resolves when
the offending agent is discontinued or its dose reduced.
For infants receiving prolonged TPN, hypertension may
result from salt and water overload, or from hypercal-
cemia caused either directly by excessive calcium intake,
or indirectly by vitamin A or D intoxication. In our case,
multiple drugs had been used, including adrenergic
drugs, aminophylline, indomethacin, dexamethasone
and long-term TPN (Figure 3A). All of them may relate
to the elevation of blood pressure.
Also, hypertension in our case during the later stage
was observed after the use of EPO for a period of time.
With the finding of elevated serum renin concentrations,
EPO-related hypertension was also considered, and the
hypertension seemed to improve after EPO was 
stopped. Although there have been some reports of
EPO-related hypertension in adult uremia cases,22,23
EPO-associated neonatal hypertension is rare.24–26
Since EPO has been recognized worldwide as a regular
therapy to reduce red blood cell transfusions in extreme-
ly premature infants,24–26 possible EPO-related hyper-
tension should be considered in these premature infants.
Furthermore, amphotericin B should be considered
to be a hypertensive factor because it was used for 1
month in this infant. Although there were no previous
case reports of neonates, 2 adults were reported to have
amphoterin B-associated hypertension.27,28 Our patient
was also treated with multiple antibiotics (Figure 3B) to
control infections,29 so infection-induced interstitial
nephritis or nephrotoxicity induced by some antibiotics
should also be considered as contributing factors.
Reviewing the medical history of this presented
case, there must be multiple factors that contributed to
his hypertension, including umbilical catheter place-
ment, CLD/BPD, unclosed PDA, sepsis and the use
of indomethacin, aminophylline, adrenergic agents,
EPO, antibiotics, amphotericin B, dexamethasone, and
TPN. All these medications and interventions may
relate to his hypertension.9–19
In conclusion, multiple factors can influence blood
pressure and may induce hypertension in high-risk pre-
mature infants. Thus, blood pressure should be checked
in high-risk neonates, and even after their discharge
from NICU. Judicious use of all medications and inter-
ventions are crucial to decrease the incidence of hyper-
tension in high-risk premature infants.
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